Neutrophil extracellular traps — web-like structures released by immune cells that can promote clotting — are increased during acute episodes and clinical relapses of immune-mediated…
Incyte will acquire Vega Therapeutics, a subsidiary of Star Therapeutics, to advance the development of VGA039, an investigational monthly injection therapy to prevent bleeds in people with von Willebrand disease (VWD). VGA039 is being evaluated as a prophylactic (preventive) treatment option for VWD in the VIVID-6 Phase…
Latest news & perspectives
A mutation in the gene ELF4 likely set the stage for a teenage boy to develop immune thrombocytopenia (ITP), according to a new report. The…
People with von Willebrand disease (VWD) had lower bone mineral density than healthy individuals in a small, single-center study, highlighting the need to consider…
